Phase IIIAndrogen Modulator
Compound 61682
Formula Pending
Molecular Mass
N/A
CAS Registry
AUTO-061682
Risk Class
MODERATE
Last Audit
Jun 10, 2108
Research Abstract
Androgen Modulator candidate engineered for endocrine support initiatives with automated dossier coverage.
Compound 61682 is a androgen modulator asset inside androgen modulator innovation track initiatives, optimized for endocrine support and performance longevity.
The dossier currently sits in phase iii with a moderate risk rating, meaning it is requires layered oversight with metabolic labs.
Supply records cite CAS AUTO-061682 with updates logged 2108-06-10.
Acquisition Protocol
Authorized research personnel may request deployment of this compound for laboratory analysis.
Primary Vectors
Endocrine supportPerformance longevity
Nomenclature
CX-61682Androgen Modulator Program 61682
Reference Material
- [1] Anubis Compound Registry • CAS AUTO-061682
- [2] Operations Pulse • Androgen Modulator innovation track
- [3] Risk Governance Ledger • MODERATE clearance for COMPOUND-61682